ACHV - Achieve Life Sciences: Nearing Commercialization Of A Best-In-Class Pharmaceutical Product For Smoking Cessation
2025-07-07 13:55:46 ET
Thesis overview
Achieve Life Sciences ( ACHV ) is a late-stage pre-commercial pharmaceutical company developing cytisinicline for smoking and e-cigarette cessation. ACHV announced a few days ago a NDA submission based on a data package which I believe warrants approval, at least from an efficacy and safety perspective. Assuming acceptance of the submission, the FDA should make a decision on approval within 12 months of submission. ACHV has dipped following an offering which in my opinions represents a good buying and trading opportunity towards the FDA decision. A long-term investment in ACHV is associated with major risks, including the need for further cash raises to support commercialization, manufacturing risks and risks associated with problematic intellectual property....
Achieve Life Sciences: Nearing Commercialization Of A Best-In-Class Pharmaceutical Product For Smoking Cessation